Get some practical advice from top experts and join our networking breakfast.
This session will focus on how you can develop your IP strategy as you seek investment, and provide tips on surviving the due diligence process.
Peter works with a long and growing list of European start-up companies, advising them on how to develop their IP strategies in a way that will build and support exit value.
He also makes sure their IP plays the part that it should within both business planning and fund raising. He has helped many of his clients successfully navigate a course through a series of funding rounds. He also sits on a number of boards for his clients so they can take full advantage of his broader commercial experience.
Building on his reputation as a leading IP strategist in the IAM Strategy 300, Peter has developed a suite of IP consultancy products addressing the need for innovation capture, IP audit and commercial strategy development for technology companies seeking private equity funding. Likewise, he has developed IP due diligence products for investors designed to evaluate and test the strength of a business’s IP. His approach provides investors with a pragmatic and cost-effective way to evaluate the IP risks associated with technology investments to ensure they get the right deal.
Peter regularly writes on the subject of IP strategy development and implementation in technology magazines such as SmallBusiness.co.uk, NS Tech and UKTN, and he has been published in the scientific journal Drug Discovery Today on the use of artificial intelligence in drug repurposing.
Fiona is an experienced patent attorney and handles a wide variety of work in the pharmaceutical, chemical and biotechnology fields.
The majority of Fiona’s work involves working with UK clients, and she has extensive experience in developing and implementing IP strategies that are aligned with commercial objectives.
Fiona deliberately tries to avoid becoming too focused on a particular sector, believing that the underlying principles of implementing an IP strategy can be applied across many industries, and to businesses of varying sizes. That said, Fiona is recognised for her expertise in pharmaceutical life cycle management, in particular, obtaining supplementary protection certificates (SPCs) and patent term extensions for approved drugs in a number of jurisdictions worldwide. She also has a particular interest in second medical use patents and has helped a number of clients achieve commercial success with re-purposed drugs.
Fiona is a regular attendee at International Federation of Intellectual Property Attorneys (FICPI) and American Intellectual Property Law Association (AIPLA) overseas conferences and also lectures on the CIPA Administrator course. In 2017, Fiona was recognised as one of Management Today’s ’35 under 35′ for her accomplishments in intellectual property.
Get some practical advice from top experts and join our networking breakfast.
The NIHR works in partnership with all life science companies and CROs to design and deliver research within the UK health and social care environment. From early stage, translational research through to later stage clinical trials, a full range of free support is available. Throughout the pandemic we have worked collaboratively across the entire UK research ecosystem to deliver research at unparalleled scale and pace. Join this session to:
Understand how the lessons learned from that experience are shaping future research delivery and what this will mean for you.
Hear about new NIHR initiatives that are already making an impact and how you can access them.
Head of External Relations
Dr Matthew Hallsworth is Head of External Relations for the NIHR Office for Clinical Research Infrastructure (NOCRI). He leads on external stakeholder relations, including engagement with the pharmaceutical industry.
NOCRI works with companies and other research partners to support collaboration with the UK’s expert investigators and research facilities funded by the UK Department of Health, from early-phase translational medicine through to later-phase clinical trials.
Prior to NOCRI Matthew was Head of Communications at the UK Clinical Research Collaboration – a partnership of government, charities, industry, the NHS, academia, regulators and patients focused on improving the clinical research environment in the UK.
Matthew has also had Research Management roles at the medical charity Asthma UK and for the Department of Health’s National R&D Programme.
During his earlier career Matthew was a Research Fellow in Respiratory Medicine at Guy’s & St Thomas’ Hospitals, London, where he completed his PhD on the mechanisms of inflammation in asthma and allergic disease.
Steve Bates has been the CEO of the UK Bioindustry Association since 2012. He currently chairs the International Council of Biotech Associations and has been a Board member of Europabio since 2015. Steve is the visible face of the vibrant UK life sciences industry to government and media. He sits on the UK’s Life Sciences Council and Life Sciences Industrial Strategy Implementation Board. Steve has championed with government effective industrial incentives like the Biomedical Cataylst which have crowded-in private sector investment into UK SMES. He has forged links for the sector across the USA, Europe and in China. In his time at the BIA Steve has developed new member groups focused on cell and gene therapy, genomics and engineered biology. A strong advocate of partnership working, Steve champions sector collaboration with research charities and academia. Proud to lead an organisation with a diverse Board with over 40% female representation, Steve is committed to next generation talent and developing the skills needed for the sector to flourish. Before the BIA, Steve worked for Genzyme and as an advisor to the UK Government of Tony Blair. He was made OBE for services to innovation in 2017.
Investing in innovation for the future of life sciences - Keynote by Indro Mukerjee
Hear directly from the new CEO of Innovate UK – tasked with developing the UK’s innovation capability, and driving investment in research and development (R&D) and technologies of the future.
Indro Mukerjee is an experienced CEO with board-level leadership experience in publicly listed, corporate multinational, new venture and private equity backed fast-moving technology and industrial companies.
Previously CEO of Watchstone Group plc – Brought in by institutions to stabilise and reshape a high-profile company operating in insurance, telematics and healthcare software and services.
At Plastic Logic, he restructured major venture capital-backed disruptive electronics company and created the FlexEnable Ltd. spin out.
At C-MAC MicroTechnology he built and sold three successful high technology companies operating in aerospace/defence, automotive and communications markets.
Indro’s main corporate leadership experience was based in the Netherlands with Philips (now NXP) Semiconductors BV, where he held several global board positions.
His earlier career included being Commercial Director within the leadership team which took VideoLogic (now Imagination Technologies) through an IPO, as well as senior management positions within Hitachi’s European semiconductor division.
Indro has a strong personal interest in the development of skills for industry and getting the best talent pipeline developed. He co-founded the UK Electronics Skills Foundation, which has developed into an innovative and successful partnership between industry and academia encouraging bright, young students to develop careers in the UK electronic systems industry.
The Life Sciences Vision sets out an ambition to “create an outstanding business environment for Life Science companies – in which incentives and structures are aligned to support company growth, innovation and investment… and bringing to bear the full financial firepower of the City of London to support companies to grow”. Our expert panel will discuss the challenges and opportunities in achieving this goal.
Since 2013, Vishal Gulati is one of the most active stage agnostic digital health investors in Europe. His portfolio of over twenty companies spans a wide range of technology platforms including digital therapeutics, AI/ML, precision medicine, omics and synthetic biology.
Vishal invests directly through his syndicates or from the funds where he has a strategic relationship (Draper Esprit and Oxford Sciences Innovations).
Vishal serves on the boards of several private companies and his public appointments include committees of Cancer Research UK, the British Heart Foundation, Innovate UK/ MRC and Rueben College in Oxford.
Previously, Vishal has worked at the Wellcome Trust and Atlas Venture. Prior to this Vishal trained as a medical doctor and clinician scientist at Nuffield Department of Medicine in Oxford and Department of Medicine at Imperial College.
Co-Head of Healthcare
Polar Capital Healthcare Team
Daniel joined Polar Capital to set up the healthcare team in 2007. He has 29 years of industry experience, comprising more than 23 years’ investment experience in the healthcare sector. Prior to joining Polar Capital, he was head of the European healthcare research team at Morgan Stanley. He also previously worked for ING Barings Furman Selz in New York following the US biotechnology sector. Before working in the investment field, Daniel worked as a research scientist for seven years with the majority of his time at Schering Plough Corporation in California. Daniel received his PhD from Cambridge University in 1995 and a first class honours degree in Biochemistry from Oxford University in 1991.
Life Sciences Investment Director
British Patient Capital
Tej Panesar is the Life Sciences Investment Director within British Patient Capital (BPC), the commercial division of the the UK’s British Business Bank focused on venture capital and UK scale-ups. Over the past 4 years he has led investments totalling £385m, including £150m into life sciences focused funds. Tej developed BPC’s life sciences investment strategy and has built out a specialist team to support BPC’s ambitions in the sector. He has a background in investment banking (Citigroup), private equity (CEO real assets fund), fintech (Crowdcube, OnBourse, Orbian) and was educated at the London School of Economics.
Equity Research Analyst, Healthcare
Julie joined Panmure Gordon in 2015 and has 20 years’ experience in Life Sciences research across a wide range of Healthcare subsectors. She previously worked at Canaccord Genuity, Piper Jaffray and Nomura having started her City career at Beeson Gregory, where she became Head of Lifesciences research. Julie has a PhD in Microbiology from the University of Kent and industry experience in both Europe and the US. She is also a panel member for NIHR i4i (invention for innovation), assessing early stage medical technologies.
Head of LifeArc Ventures
Clare is an experienced life sciences corporate finance and investment specialist, with significant expertise in growth funding for innovative life sciences companies in the private and public markets. Clare has been on the BIA board since January 2019 and is now seeking re-election. Clare joined LifeArc in July 2020 as Head of LifeArc Ventures, responsible for developing and implementing a strategy for LifeArc’s investments across the life sciences sector, enhancing LifeArc’s commitment to funding the translation of promising life sciences research. LifeArc’s strategic investments in innovation are a key component of its charitable model, supporting both the ability to create impact for the benefit of patients and aims to contribute to its long-term sustainability.
Clare was recently at FTSE250 listed healthcare investment company Syncona Investment Management, where she was Head of Corporate Development. She also has over 15 years’ experience in healthcare investment banking and was Managing Director and Co-Head of Healthcare and Life Sciences at Numis Securities, specialising in equity capital markets and M&A for London listed companies. Clare is also a Non-Executive Director at the Stevenage Bioscience Catalyst.
Clare has been an enthusiastic supporter of the life sciences sector and understands the opportunities and challenges that funding growing companies in the sector brings. She is currently a member of the BIA Audit Committee and intends to continue in that role.
Access to NHS data as lifeblood for UK biotech company growth
Making the NHS ‘the country’s most powerful driver of innovation’ is now a government priority – but how do we ensure that the UK’s world-leading innovative life science SMEs are incorporated into this strategy?
Emma is CEO at Weatherden, a drug development route-to-market design, strategy and execution consulting group. She has built multiple companies with breakthrough therapies; and is bringing to market deep tech solutions that will transform clinical trial design efficiency alongside property ventures that will pioneer a new hybrid network of biotech innovation clusters across Britain and Europe. Prior to Weatherden, Emma worked in the life sciences division at KPMG before moving into technical advisory, followed by three years at SV Health Investors working on biotech company creation in immunology and oncology. She advises early-stage life sciences and EIS funds, is passionate about encouraging broader participation in STEM and is active mentor to young entrepreneurs.
During her time at Weatherden, Emma has witnessed first-hand the many barriers to innovation, and is passionate about accelerating better drugs to patients, equality of access to clinical trials and ensuring the UK is best placed to maintain its position on the world stage and attract more investment from overseas.
CEO and Co-Founder
Steve is a serial technology entrepreneur with over 25 years’ experience developing and commercializing ground-breaking data science and informatics in the healthcare, life sciences and agri-food sectors.
Never afraid to innovate, Steve has an established track record in building world-class companies, teams and products working at senior levels in the UK, EU and US for Fortune 500 and start-up companies. He is a former Global Director of Research Informatics for Astra A/B and has consulted with drug discovery and safety teams in over 20 biopharma companies. Steve has held CxO positions and led teams in several international businesses, supplying innovative computational biology, chemistry and semantic data integration tools. He was involved in Oxford Molecular’s IPO and the acquisition and integration of 11 companies. He is an Advisory Council member for Breast Cancer Now and UKCRC.
We’ve asked six experts for their top picks of up-and-coming life science companies. Come and listen to the future…
Founded by the team that pioneered data-driven design of future-proof vaccines at the Jenner Institute University of Oxford (home of the AZ vaccine), Baseimmune uses its unique computational platform to predict pathogens future mutations to design vaccines against novel and complex diseases. Joshua, its CEO, has worked on over 10 vaccines during his time at the Jenner Institute, Imperial College London and Baseimmune with two currently in human clinical trials tackling complex diseases such as HPV, Dengue and Malaria. He’s also developed a number of vaccines directly with the pharma industry.
CSO and Co-founder
Alex is CSO and co-founder of Enedra Therapeutics, a recently founded biotech using AI and synthetic lethality to develop the first anti-cancer drugs that defeat tumour evolution. He has over ten years’ experience the pharma industry leading drug discovery research teams in machine learning, computational biology and genomics at Pfizer, GSK and Lonza. He received his PhD and MBA from the European Bioinformatics Institute and Cambridge University and held post-doctoral positions at the University of Kyoto and Cambridge.
Debora is Enhanc3D Genomics' CEO and joined the founding team in early 2020. She has a keen interest in disruptive technologies that have potential to benefit human healthcare. She brings a wealth of experience in technology development, together with a track record of successfully delivering large-scale projects in academia and industry. In previous roles Debora led a cancer signature discovery (Director of Biomarker Discovery at Cambridge Epigenetix), directed and managed the laboratory’s research on large population studies (Head of laboratory, MRC Epidemiology, University of Cambridge) and worked on the development of the Oxford Nanopore’s technology. At Enhanc3D Genomics, Debora is leading the development of the platform, establishing the internal research programmes, strengthening the partnerships and advocating the advent of the 3D genomics era.
Enhanc3D Genomics is a functional genomics spinout company from the Babraham Institute (Cambridge, UK) leveraging a disruptive technology to profile three-dimensional (3D) genome folding at high resolution. Understanding DNA organisation and long-distance interactions allows to link gene enhancers and non-coding genetic variants to their target genes and holds promise to unlock disease-related genetics for therapeutic discovery.
A molecular biologist with 15+ years of experience in Stem Cell biology, a PhD. in cell biology and a MSc. in Biotechnology. The last 5 years I have lead a research group that focuses on the underlying mechanisms of soft tissue regeneration, mentored a dozen students and published more than 20 papers. Born and raised in academia, I recently started to make my way into the startup world. Especially interested in how to better bring innovation from the bench to the bedside, I co-founded MultiplAI Health to make preventative screening of cardiovascular diseases available to everyone in the world.
Delivering on the promises of data technology for UK bioscience: Launch of BIA’s Data technology in life sciences
Our expert panel will discuss the opportunities for - and the challenges that face UK data-driven companies working in life sciences. From investment gaps to lack of regulatory guidance; lack of access to data and big tech collaboration, we discuss next steps in ensuring that UK companies are supported to grow their world-leading capabilities.
Entrepreneur-in-residence, Francis Crick Institute; CBO, Autifony Therapeutics Ltd
Francis Crick Institute
Barbara has worked on the commercial side of life sciences for thirty years, first in a large organisation (ICI/Zeneca/AstraZeneca), before transitioning to the entrepreneurial world of biotech.
Barbara joined the Francis Crick Institute in January 2018 as Entrepreneur-in-residence, where amongst other things, she helps to run an accelerator called KQ Labs, which is focused on start-ups making use of data/AI applied to health. She is also Chief Business officer of Autifony, where she is responsible for strategic partnering, fundraising and commercial aspects of drug development for CNS disorders. In December 2017 Autifony signed a major collaboration with Boehringer Ingelheim. Barbara was also Chair of Puridify, a UCL spin-out with a breakthrough biotherapeutics purification technology, which was acquired by GE in November 2017. She chairs the LifeArc Seed Fund investment committee, and is on the Cambridge Enterprise Seed Fund Investment Committee.
Previously, Barbara was CEO of Stabilitech, and she was Commercial Director at Arrow Therapeutics until the company was acquired by AstraZeneca. Barbara was also Senior Business Development Manager at Celltech.
Barbara has a BA and D Phil in Chemistry from the University of Oxford, and is a Sloan Fellow from London Business School.
Manish has a doctorate in mathematical modelling with an emphasis on dealing with large, complex datasets. He is the technical architect of Jiva.ai, a new machine learning algorithm that will form the basis of a new breed of AIs.
Dr Andy Richards CBE
Closed Loop Medicine / Congenica
Andy is an entrepreneur and investor with an established track record in founding and scaling up innovative Life-science, Biotechnology and Digital Health companies in the UK. He is currently Chairman of Congenica, Abcodia, Closed Loop Medicine, Arecor and the Babraham Research Campus and is a Director of Ieso Digital Health, Owlstone Medical, and Cancer Research Technology (the commercial board of CR-UK). He is an advisor to several investment funds, including Cambridge Innovation Capital and the UCL Technology Fund, and is Chair of the CRUK Seed Fund and a Director of the Scale-Up Institute.
Andy is a Cambridge Graduate with a PhD in Chemistry and an early career spanning positions with ICI (now AstraZeneca) and PA Technology. He was a founder and executive director of Chiroscience plc until its merger with Celltech in 1999 and since that time he has founded, invested in and helped to scale more than 30 innovative ventures including companies such as Vectura, Arakis, Cambridge Biotechnology Ltd and Geneservice. Andy is also a founder member of the Cambridge Angels.
Andy is passionate about science and the translation of science to do good for society. The Life-sciences and Healthcare sectors provide the perfect arena for translating science into technology that can help people around the world. He received a CBE for services to investment in life-sciences in 2015.
The Golden Age of Biology has arrived - Keynote by Jonathan Milner
Jonathan Milner is this year's winner of the BIA Lifetime Achievement Award for his long-standing and impressive support of the sector through a number of roles. In this short keynote Jonathan will give his perspective on the most astonishing discoveries in Biology since starting his career in the early 90s with reference to some of the most exciting companies at the forefront of exploiting these discoveries and their impact on human health.
Jonathan Milner, Founder of Abcam plc, is an experienced entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 60 companies and has assisted three technology companies to IPO on the London AIM Stock exchange.
Jonathan gained his doctorate in Molecular Genetics at Leicester University after graduating in Applied Biology at Bath. From 1992–95, he was a post-doctoral researcher at Bath, following which he worked at the University of Cambridge in the lab of Professor Tony Kouzarides studying cancer. He identified the market opportunity for supplying high-quality antibodies to support protein interaction studies, and in 1998, founded Abcam with David Cleevely and Professor Tony Kouzarides.
Jonathan is Chairman of Axol Bioscience Ltd and Camallergy Ltd and non-executive director of PhoreMost Ltd, Syndicate Room Ltd, Start Codon Ltd and HealX Ltd